The broad mission of the Specimen Accessioning Core (SAC) is to provide a centralized resource for collecting and processing samples of blood, bone marrow, and tumor cells from patients with malignancies as well as from normal volunteer donors and to facilitate and support the ongoing laboratory and clinical research within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC).
The specific aims of the SAC are to: 1) centralize accessioning of patient specimens, 2) provide routine processing of patient specimens and tissue samples utilizing standard laboratory procedures as well as individualized processing to support clinical trials, 3) store samples in a controlled and monitored'environment to ensure sample integrity prior to utilization, 4) provide a mechanism to safely bank tissues for future research by maintaining an active IRB-approved clinical trial (currently, RPN #00-01-27-09, Tissue and Cell Procurement Protocol) that assures subjects not otherwise involved in an active clinical trial are able to donate tissues for research, that they are provided proper information concerning the research nature of the bank, and that informed consent is obtained and documented in a HIPAA-compliant manner that maximizes subject confidentiality, 5) distribute banked samples to individual investigators with IRB-approved research questions in a fair and equitable manner and maintain a secure, relational database that includes detailed information on the handling and processing of the sample, along with pertinent clinical and demographic data that correlate to the specimen, 6) provide expertise and support for investigators including, but not limited to, cellular processing, development of correlative biologic tests for clinical trials, pharmacokinetic and pharmacodynamic planning and analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-47
Application #
7821299
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
47
Fiscal Year
2009
Total Cost
$110,006
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications